lucatumumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458270096

| type = mab

| mab_type = mab

| source = u

| target = CD40

| tradename =

| pregnancy_category =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 903512-50-5

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = P0EP9VFC4R

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D08942

| chemical_formula =

| molecular_weight = 146

| molecular_weight_comment = kg/mol

}}

Lucatumumab (CHIR 12.12 or HCD122){{cite journal | vauthors = Hassan SB, Sørensen JF, Olsen BN, Pedersen AE | title = Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials | journal = Immunopharmacology and Immunotoxicology | volume = 36 | issue = 2 | pages = 96–104 | date = April 2014 | pmid = 24555495 | doi = 10.3109/08923973.2014.890626 | s2cid = 21840914 }} is a human monoclonal antibody against CD40[https://web.archive.org/web/20110604012853/http://www.ama-assn.org/ama1/pub/upload/mm/365/lucatumumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab], American Medical Association. development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma.{{cite web|title=Lucatumumab|url=http://adisinsight.springer.com/drugs/800013077|publisher=AdisInsight|access-date=20 February 2017|language=en}}

It is an antagonist to CD40 that was created by scientists at Chiron using Abgenix' XenoMouse transgenic mouse to generate fully human antibodies.{{cite web|title=Press release: XOMA and Chiron Announce Preclinical Data Presentations on CHIR-12.12 at American Hematology Conference|url=http://www.businesswire.com/news/home/20041202005701/en/XOMA-Chiron-Announce-Preclinical-Data-Presentations-CHIR-12.12|publisher=XOMA and Chiron vis Businesswire|language=en|date=December 2, 2004}}{{cite journal| vauthors = Weng WK, Tong X, Luqman M, Levy R |title=(Poster Session No. 627-II) A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma.|journal=Blood|date=16 November 2004|volume=104|issue=11|pages=3279|doi=10.1182/blood.V104.11.3279.3279|url=http://www.bloodjournal.org/content/104/11/3279|language=en|issn=0006-4971|url-access=subscription}} It was made part of the collaboration between Chiron and Xoma that the companies commenced in 2004.{{cite news|title=Chiron and Xoma in MAb deal - Pharmaceutical industry news|url=http://www.thepharmaletter.com/article/chiron-and-xoma-in-mab-deal|work=The Pharma Letter|date=March 8, 2004|language=en}}. Part of Xoma's 10-K filed 2004-03-15. [https://www.sec.gov/Archives/edgar/data/791908/000119312504042254/0001193125-04-042254-index.htm Index page] at SEC Edgar. {{cite web|title=Exhibit 10.50: Agreement, dated Feb 27, 2004, by and btwn Chiron Corp and XOMA|url=https://www.sec.gov/Archives/edgar/data/791908/000119312504042254/dex1050.htm|publisher=Xoma via SEC Edgar}}{{cite web|title=Exhibit 10.2 Amended Research, Development and Commercialization Agreement|url=https://www.sec.gov/Archives/edgar/data/791908/000119312505160702/dex102.htm|website=www.sec.gov|publisher=Xoma via SEC Edgar|date=May 26, 2005}} Novartis took over the project when it acquired Chiron in 2005.{{cite news| vauthors = Tansey B |title=Novartis to buy Chiron / Swiss pharmaceutical giant to pay $5.1 billion|url=http://www.sfgate.com/business/article/Novartis-to-buy-Chiron-Swiss-pharmaceutical-2598690.php|work=San Francisco Chronicle|date=November 1, 2005}}{{cite web|title=Press Release: XOMA Restructures Drug Development Collaboration Including Oncology Drug Candidate HCD122 (NASDAQ:XOMA)|url=http://investors.xoma.com/releasedetail.cfm?ReleaseID=346609|publisher=Xoma|language=en|date=November 10, 2008|access-date=February 20, 2017|archive-date=February 20, 2017|archive-url=https://web.archive.org/web/20170220173601/http://investors.xoma.com/releasedetail.cfm?ReleaseID=346609|url-status=dead}}

In in vitro studies, it inhibited cell proliferation induced by CD40 ligands and induced cell lysis.{{cite web| work = NCI Drug Dictionary | title = Lucatumumab|url=https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=432936|publisher= U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI) |access-date=20 February 2017 |date = 2011-02-02}}

Over three Phase 1 trials in multiple myeloma and chronic lymphocytic leukemia, the companies made an effort to determine the optimal dose, and obtained unclear results. The Phase I part of a planned Phase I/II trial in multiple myeloma was started in 2005, and in 2012 was updated to Phase II and closed; as of 2014 the results had not been published.